LB PHARMACEUTICALS INC (LBRX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$321.5M
Cash & Equivalents
$23.3M
Quarterly Burn Rate
41 mo
Est. Cash Runway
$945M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-06-01 | Phase3 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07363577 | Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia | PHASE3 | Recruiting | 456 |
| NCT07494305 | Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. | PHASE2 | Recruiting | 320 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.